Compare FOR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | AMPH |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2007 | 2014 |
| Metric | FOR | AMPH |
|---|---|---|
| Price | $30.31 | $28.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $31.75 | $31.00 |
| AVG Volume (30 Days) | 197.6K | ★ 297.9K |
| Earning Date | 01-20-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.27 | 2.27 |
| Revenue | ★ $1,685,000,000.00 | $723,305,000.00 |
| Revenue This Year | $0.52 | $1.37 |
| Revenue Next Year | $7.72 | $4.84 |
| P/E Ratio | ★ $9.27 | $12.56 |
| Revenue Growth | ★ 15.89 | N/A |
| 52 Week Low | $18.00 | $20.39 |
| 52 Week High | $30.74 | $32.69 |
| Indicator | FOR | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 57.21 |
| Support Level | $29.13 | $27.24 |
| Resistance Level | $29.87 | $29.09 |
| Average True Range (ATR) | 0.95 | 0.89 |
| MACD | 0.32 | 0.08 |
| Stochastic Oscillator | 93.22 | 73.77 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.